📣 VC round data is live. Check it out!

YSB Valuation Multiples

Discover revenue and EBITDA valuation multiples for YSB and similar public comparables like Haypp Group, Cawachi, Dimed SA, Nice One and more.

YSB Overview

About YSB

YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The Group mainly engaged in i) wholesales of pharmaceutical and healthcare products offline or online through its online platform; ii) retail of pharmaceutical and healthcare products through its retail shops; iii) operating online platform that enable the pharmaceutical distributors and vendors to sell their own pharmaceutical and healthcare products using the Group’s online platform; iv) providing SaaS solution to downstream pharmacies to streamline their inventory management; and v) providing medical testing services to primary healthcare institutions. The Group principally operates in the PRC and generates the majority of its revenues from the PRC.


Founded

2018

HQ

China

Employees

6.8K

Website

ysbang.cn

Financials (FY)

Revenue: $3B
EBITDA: $44M

EV

$213M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

YSB Financials

YSB reported last fiscal year revenue of $3B and EBITDA of $44M.

In the same fiscal year, YSB generated $338M in gross profit, $44M in EBITDA, and $22M in net income.


YSB P&L

In the most recent fiscal year, YSB reported revenue of $3B and EBITDA of $44M.

YSB is profitable as of last fiscal year, with gross margin of 11%, EBITDA margin of 1%, and net margin of 1%.

See analyst estimates for YSB
Last FY202320242025202620272028
Revenue$3B$2B$3B$3B
Gross Profit$338M$255M$266M$338M
Gross Margin11%10%10%11%
EBITDA$44M($449M)$23M$44M
EBITDA Margin1%(18%)1%1%
EBIT Margin0%(0%)(0%)0%
Net Profit$22M($469M)$2M$22M
Net Margin1%(19%)0%1%

Financial data powered by Morningstar, Inc.

YSB Stock Performance

YSB has current market cap of $420M, and enterprise value of $213M.

Market Cap Evolution


YSB's stock price is $0.61.

YSB share price decreased by 7.1% in the last 30 days, and by 51.3% in the last year.

YSB has an EPS (earnings per share) of $0.03.

See more trading valuation data for YSB
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$213M$420M-6.3%-7.1%-2.9%-51.3%$0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

YSB Valuation Multiples

YSB trades at 0.1x EV/Revenue multiple, and 4.8x EV/EBITDA.

See NTM and 2027E valuation multiples for YSB

YSB Financial Valuation Multiples

As of May 8, 2026, YSB has market cap of $420M and EV of $213M.

YSB has a P/E ratio of 18.8x.

Last FY202320242025202620272028
EV/Revenue0.1x0.1x0.1x0.1x
EV/EBITDA4.8x(0.5x)9.4x4.8x
EV/EBIT20.9x(29.7x)(17.4x)20.9x
EV/Gross Profit0.6x0.8x0.8x0.6x
P/E18.8x(0.9x)190.4x18.8x
EV/FCF2.3x3.4x2.3x2.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified YSB Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

YSB Margins & Growth Rates

In the most recent fiscal year, YSB reported gross margin of 11%, EBITDA margin of 1%, and net margin of 1%.

See estimated margins and future growth rates for YSB

YSB Margins

Last FY20242025202720282029
Gross Margin11%10%11%
EBITDA Margin1%1%1%
EBIT Margin0%(0%)0%
Net Margin1%0%1%
FCF Margin3%4%3%

YSB Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth5%17%
Gross Profit Growth4%27%
EBITDA Growth(105%)96%
EBIT Growth71%(183%)
Net Profit Growth(100%)914%
FCF Growth46%(2%)

Data powered by FactSet, Inc. and Morningstar, Inc.

YSB Operational KPIs

YSB's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for YSB
Last FY202320242025202620272028
Revenue per Employee$0.5M
Opex per Employee$0.0M
S&M Expenses to Revenue8%8%8%8%
G&A Expenses to Revenue2%2%2%2%
R&D Expenses to Revenue0%1%1%0%
Opex to Revenue11%11%11%11%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

YSB Competitors

YSB competitors include Haypp Group, Cawachi, Dimed SA, Nice One, BHG Group, Wish, JZJ Chain Drugstore, Aramis Group, DocMorris and Terminal X.

Most YSB public comparables operate across Pharmacies, Vertical E-commerce, Consumer E-commerce and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Haypp Group1.0x0.9x17.5x17.3x
Cawachi0.2x0.2x4.0x
Dimed SA0.6x0.6x6.2x9.6x
Nice One1.5x46.1x
BHG Group0.5x0.5x7.1x7.2x
Wish(7.9x)
JZJ Chain Drugstore0.7x5.8x
Aramis Group0.2x0.2x6.1x6.7x

This data is available for Pro users. Sign up to see all YSB competitors and their valuation data.

Start Free Trial

YSB Funding History

Before going public, YSB raised $495M in total equity funding, across 5 rounds.

Last private valuation of YSB was $533M, after raising $133M in December 2018 from DCM Ventures, H. Capital, and Tiger Global.


YSB Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-21Series EBaidu; Green Pine Capital Partners; Pearl River Investment; SFUND$270M
Dec-18Series DDCM Ventures; H. Capital; Tiger Global$133M$533MYSB is a technology company that traces its operational history back to 2015 when it first commenced operations and launched the YSB App. The company completed a Series D funding round on 30 January 2019, raising $133.2 million at a post-money valuation of $533.2 million, representing a share price of $4.00 per share with investors holding 62.7% ownership at that stage. The round reflected significant growth trajectory, following earlier fundraising milestones including a Series C-2 round in September 2018 that valued the company at $271.4 million post-money. Tiger Global participated as an investor alongside other backers including DCM Ventures and H. Capital.
Jun-18Series CDCM Ventures; ECC Capital; Green Pine Capital Partners; Shunwei Capital; SIG China (SIG Asia Investments)$65M$201MYSB (Yaoshibang or Pharmacist Bang, 药师帮) is a Guangzhou-based online pharmacy trading platform connecting pharmaceutical manufacturers with retailers such as pharmacies and primary healthcare institutions, alongside education and SaaS solutions like YSB eLearn, ClouDiagnos, and wePharmacy. The platform facilitates B2B transactions in the pharmaceutical supply chain, serving over 150,000 active drug terminals as of June 2018 with monthly GMV exceeding CNY 500 million. It operates an upstream Yaoshibang Platform for online marketplace and targeted product launches, a downstream general self-operation business, and other SaaS offerings. In June/July 2018, YSB (also referred to as YSBang) raised its Series C round of approximately CNY 420 million (USD 65-66 million), led by Shunwei Capital Partners and DCM Ventures, with participation from investors including SIG China (SIG Asia Investments), ECC Capital (potentially aligned with other funds), and Green Pine Capital Partners. The HKEX prospectus details a Series C-1 tranche on 2 July 2018 raising RMB 160 million at a post-investment valuation of RMB 1,385 million, followed by Series C-2 on 14 September 2018 raising US$40.8 million at US$271.4 million valuation; this aligns closely with the described round timing and investors. Prior rounds included Series Seed (May 2015, RMB 16M at RMB 100M val), Series A (Sep 2016, RMB 55M at RMB 230M), and Series B (Apr 2018, RMB 108M at RMB 588M). The company continued raising capital post-2018, including Series D in Dec 2018 and Jan 2019 (up to US$133.2M at US$533.2M val), Series E-1 in Feb 2021 (US$150M at US$1.35B), and later Series D in Jun 2021 ($270M). Total equity funding reached ~$495M across 6 rounds by 2024, with recent 2024 net profit of $4.19M USD and EBITDA $4.59M USD.
Feb-17Series BCo-Power Capital Management; Fosun International; Green Pine Capital Partners; Ivy Capital$16M
Apr-16Series AFosun Pharma$11M

YSB Investment Activity

YSB has invested in 1 company to date.

Latest investment by YSB was on February 28th 2024. YSB invested in Ruize Health in their $1M Strategic investment round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by YSB

Ruize Health
Description
Ruize Health is a commercial insurance provider operating in the Chinese market with a specialization in health consumption coverage. The company delivers policies that address medical treatments, wellness programs, and preventive healthcare needs for individuals and businesses. Its product lineup includes supplemental health insurance plans designed to complement public systems, targeting urban consumers in provinces like Guangdong and Jiangsu. Ruize Health maintains partnerships with hospitals and clinics to facilitate claims processing and service delivery across eastern China.
HQ CountryChina
HQ City
Shanghai
Deal Date28 Feb 2024
RoundStrategic investment
Raised$1M
InvestorsYSB
Valuation$11M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all YSB investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About YSB

When was YSB founded?YSB was founded in 2018.
Where is YSB headquartered?YSB is headquartered in China.
How many employees does YSB have?As of today, YSB has over 6K employees.
Who is the CEO of YSB?YSB's CEO is Buzhen Zhang.
Is YSB publicly listed?Yes, YSB is a public company listed on HKEX.
What is the stock symbol of YSB?YSB trades under 09885 ticker.
When did YSB go public?YSB went public in 2023.
Who are competitors of YSB?YSB main competitors include Haypp Group, Cawachi, Dimed SA, Nice One, BHG Group, Wish, JZJ Chain Drugstore, Aramis Group, DocMorris, Terminal X.
What is the current market cap of YSB?YSB's current market cap is $420M.
What is the current revenue of YSB?YSB's last fiscal year revenue is $3B.
What is the current EV/Revenue multiple of YSB?Current revenue multiple of YSB is 0.1x.
Is YSB profitable?No, YSB is not profitable.
How many companies YSB has acquired to date?YSB hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies YSB has invested to date?As of May 2026, YSB has invested in 1 company.
What was the last YSB investment?On 28th February 2024 YSB invested in Ruize Health, participating in a $1M Strategic investment round at $11M valuation.
In what companies YSB invested in?YSB invested in Ruize Health.

See public comps similar to YSB

Lists including YSB

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial